1
|
Giakoumaki M, Lambrou GI, Vlachodimitropoulos D, Tagka A, Vitsos A, Kyriazi M, Dimakopoulou A, Anagnostou V, Karasmani M, Deli H, Grigoropoulos A, Karalis E, Rallis MC, Black HS. Type I Diabetes Mellitus Suppresses Experimental Skin Carcinogenesis. Cancers (Basel) 2024; 16:1507. [PMID: 38672589 PMCID: PMC11048394 DOI: 10.3390/cancers16081507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Revised: 04/07/2024] [Accepted: 04/10/2024] [Indexed: 04/28/2024] Open
Abstract
This study explores the previously uncharted territory of the effects of ultraviolet (UV) radiation on diabetic skin, compared to its well-documented impact on normal skin, particularly focusing on carcinogenesis and aging. Employing hairless SKH-hr2, Type 1 and 2 diabetic, and nondiabetic male mice, the research subjected these to UV radiation thrice weekly for eight months. The investigation included comprehensive assessments of photoaging and photocarcinogenesis in diabetic versus normal skin, measuring factors such as hydration, trans-epidermal water loss, elasticity, skin thickness, melanin, sebum content, stratum corneum exfoliation and body weight, alongside photo documentation. Additionally, oxidative stress and the presence of hydrophilic antioxidants (uric acid and glutathione) in the stratum corneum were evaluated. Histopathological examination post-sacrifice provided insights into the morphological changes. Findings reveal that under UV exposure, Type 1 diabetic skin showed heightened dehydration, thinning, and signs of accelerated aging. Remarkably, Type 1 diabetic mice did not develop squamous cell carcinoma or pigmented nevi, contrary to normal and Type 2 diabetic skin. This unexpected resistance to UV-induced skin cancers in Type 1 diabetic skin prompts a crucial need for further research to uncover the underlying mechanisms providing this resistance.
Collapse
Affiliation(s)
- Maria Giakoumaki
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - George I. Lambrou
- Choremeio Research Laboratory, First Department of Pediatrics, School of Health Sciences, Medical School, National and Kapodistrian University of Athens, Thivon & Levaeias 8, Goudi, 11527 Athens, Greece;
- Research Institute of Maternal and Child Health & Precision Medicine, National and Kapodistrian University of Athens, Thivon & Levadeias 8, 11527 Athens, Greece
| | - Dimitrios Vlachodimitropoulos
- Department of Forensic Medicine and Toxicology, Medical School, National and Kapodistrian University of Athens, 75, Mikras Asias Street, 11527 Athens, Greece;
| | - Anna Tagka
- First Department of Dermatology and Venereology, ‘Andreas Syggros” Hospital, School of Medicine, National and Kapodistrian University of Athens, Ionos Dragoumi 5, 11621 Athens, Greece;
| | - Andreas Vitsos
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Maria Kyriazi
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Aggeliki Dimakopoulou
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Vasiliki Anagnostou
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Marina Karasmani
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Heleni Deli
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Andreas Grigoropoulos
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Evangelos Karalis
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Michail Christou Rallis
- Division of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis, 15784 Athens, Greece; (M.G.); (A.V.); (M.K.); (A.D.); (V.A.); (M.K.); (H.D.); (A.G.); (E.K.)
| | - Homer S. Black
- Department of Dermatology, Baylor College of Medicine, Houston, TX 77030, USA;
| |
Collapse
|
2
|
Liang K, Feliciano JL, Marrone KA, Murray JC, Hann CL, Anagnostou V, Tackett SA, Shin EJ, Hales RK, Voong KR, Battafarano RJ, Yang SC, Broderick SR, Ha JS, Forde PM, Brahmer JR, Lam VK. Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis. ESMO Open 2024; 9:102199. [PMID: 38071928 PMCID: PMC10837776 DOI: 10.1016/j.esmoop.2023.102199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 10/30/2023] [Accepted: 11/15/2023] [Indexed: 01/26/2024] Open
Abstract
BACKGROUND Brain metastasis (BRM) is uncommon in gastroesophageal cancer. As such, clinicopathologic and molecular determinants of BRM and impact on clinical outcome remain incompletely understood. METHODS We retrospectively analyzed clinicopathologic data from advanced esophageal/gastroesophageal junction (E/GEJ) patients at Johns Hopkins from 2003 to 2021. We investigated the association between several clinical and molecular features and the occurrence of BRM, with particular focus on human epidermal growth factor receptor 2 (HER2) overexpression. Survival outcomes and time to BRM onset were also evaluated. RESULTS We included 515 patients with advanced E/GEJ cancer. Tumors were 78.3% esophageal primary, 82.9% adenocarcinoma, 31.0% HER2 positive. Cumulative incidence of BRM in the overall cohort and within HER2+ subgroup was 13.8% and 24.3%, respectively. HER2 overexpression was associated with increased risk of BRM [odds ratio 2.45; 95% confidence interval (CI) 1.10-5.46]. On initial presentation with BRM, 50.7% had a solitary brain lesion and 11.3% were asymptomatic. HER2+ status was associated with longer median time to onset of BRM (14.0 versus 6.3 months, P < 0.01), improved median progression free survival on first-line systemic therapy (hazard ratio 0.35, 95% CI 0.16-0.80), and improved median overall survival (hazard ratio 0.20, 95% CI 0.08-0.54) in patients with BRM. CONCLUSION HER2 overexpression identifies a gastroesophageal cancer molecular subtype that is significantly associated with increased risk of BRM, though with later onset of BRM and improved survival likely reflecting the impact of central nervous system-penetrant HER2-directed therapy. The prevalence of asymptomatic and solitary brain lesions suggests that brain surveillance for HER2+ patients warrants prospective investigation.
Collapse
Affiliation(s)
- K Liang
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J L Feliciano
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - K A Marrone
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J C Murray
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - C L Hann
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V Anagnostou
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - S A Tackett
- Department of Medicine, Biostatistics, Epidemiology and Data Management (BEAD) Core, Johns Hopkins University School of Medicine, Baltimore, USA
| | - E J Shin
- Department of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine, Baltimore, USA
| | - R K Hales
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, USA
| | - K R Voong
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, USA
| | - R J Battafarano
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - S C Yang
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - S R Broderick
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J S Ha
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - P M Forde
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J R Brahmer
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V K Lam
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
| |
Collapse
|
3
|
Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R. Corrigendum to "HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade": [Annals of Oncology volume 33 (2022) 728-738]. Ann Oncol 2023:S0923-7534(23)00145-X. [PMID: 37121856 DOI: 10.1016/j.annonc.2023.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023] Open
Affiliation(s)
- X M Shao
- Institute for Computational Medicine, Johns Hopkins University, Baltimore; Department of Biomedical Engineering, Johns Hopkins University, Baltimore
| | - J Huang
- Institute for Computational Medicine, Johns Hopkins University, Baltimore
| | - N Niknafs
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - A Balan
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - C Cherry
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J White
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V E Velculescu
- Institute for Computational Medicine, Johns Hopkins University, Baltimore; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V Anagnostou
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
| | - R Karchin
- Institute for Computational Medicine, Johns Hopkins University, Baltimore; Department of Biomedical Engineering, Johns Hopkins University, Baltimore; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
| |
Collapse
|
4
|
Scott S, Hu C, Smith K, Anagnostou V, Lee J, Spicer J, Illei P, Prophet E, Rosner S, Ettinger D, Feliciano J, Hann C, Lam V, Levy B, Murray J, Brahmer J, Forde P, Marrone K. EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Rosner S, Zaidi N, Wang H, Smith K, Nauroth J, Guo M, Fitzpatrick P, Riemer J, Barnes A, Wenga P, Feliciano J, Hann C, Lam V, Murray J, Scott S, Anagnostou V, Levy B, Forde P, Brahmer J, Jaffee E, Marrone K. EP08.01-086 Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
6
|
Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. Ann Oncol 2022; 33:728-738. [PMID: 35339648 PMCID: PMC10621650 DOI: 10.1016/j.annonc.2022.03.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 03/10/2022] [Accepted: 03/11/2022] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Whereas human leukocyte antigen (HLA) class I mutation-associated neoantigen burden has been linked with response to immune checkpoint blockade (ICB), the role of HLA class II-restricted neoantigens in clinical responses to ICB is less studied. We used computational approaches to assess HLA class II immunogenic mutation (IMM) burden in patients with melanoma and lung cancer treated with ICB. PATIENTS AND METHODS We analyzed whole-exome sequence data from four cohorts of ICB-treated patients with melanoma (n = 110) and non-small-cell lung cancer (NSCLC) (n = 123). MHCnuggets, a neural network-based model, was applied to estimate HLA class II IMM burdens and cellular fractions of IMMs were calculated to assess mutation clonality. We evaluated the combined impact of HLA class II germline genetic variation and class II IMM burden on clinical outcomes. Correlations between HLA class II IMM burden and density of tumor-infiltrating lymphocytes were computed from expression data. RESULTS Responding tumors harbored a significantly higher HLA class II IMM burden for both melanoma and NSCLC (P ≤ 9.6e-3). HLA class II IMM burden was correlated with longer survival, particularly in the NSCLC cohort and in the context of low intratumoral IMM heterogeneity (P < 0.001). HLA class I and II IMM landscapes were largely distinct suggesting a complementary role for class II IMMs in tumor rejection. A higher HLA class II IMM burden was associated with CD4+ T-cell infiltration and programmed death-ligand 1 expression. Transcriptomic analyses revealed an inflamed tumor microenvironment for tumors harboring a high HLA class II IMM burden. CONCLUSIONS HLA class II IMM burden identified patients with NSCLC and melanoma that attained longer survival after ICB treatment. Our findings suggest that HLA class II IMMs may impact responses to ICB in a manner that is distinct and complementary to HLA class I-mediated responses.
Collapse
Affiliation(s)
- X M Shao
- Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA
| | - J Huang
- Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA
| | - N Niknafs
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - A Balan
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - C Cherry
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - J White
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V E Velculescu
- Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA
| | - V Anagnostou
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
| | - R Karchin
- Institute for Computational Medicine, Johns Hopkins University, Baltimore, USA; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA.
| |
Collapse
|
7
|
Forde P, Kindler H, Zauderer M, Sun Z, Ramalingam S, Anagnostou V, Brahmer J, Nowak A, Kok P, Brown C, Yip S, Cook A, Lesterhuis W, Hughes B, Pavlakis N, Stockler M, O'Byrne K. DREAM3R: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma: A Phase 3 Randomised Trial. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.10.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Niknafs N, Forde P, Lanis M, Belcaid Z, Smith K, Sun Z, Balan A, White J, Cherry C, Shivakumar A, Shao X, Kindler H, Purcell T, Santana-Davila R, Dudek A, Borghaei H, Illei P, Velculescu V, Karchin R, Brahmer J, Ramalingam S, Anagnostou V. OA12.01 Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Lam V, Hales R, Feliciano J, Voong K, Shin E, Smith K, Anagnostou V, Velculescu V, Thompson E, Sears C, Pardoll D, Rodavia H, Schneider H, Hu C, Amjad A, Guerrieri P, Jobe B, Zaidi A, Kelly R. 1497TiP REACTION – a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced esophagogastric cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
10
|
Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 2019; 29:1853-1860. [PMID: 29982279 DOI: 10.1093/annonc/mdy218] [Citation(s) in RCA: 285] [Impact Index Per Article: 57.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant therapy, defined as ≤10% residual viable tumor (RVT), may predict improved long-term patient outcome. However, %RVT calculations were developed in the context of chemotherapy (%cRVT). An immune-related %RVT (%irRVT) has yet to be developed. Patients and methods The first trial of neoadjuvant anti-PD-1 (nivolumab, NCT02259621) was just reported. We analyzed hematoxylin and eosin-stained slides from the post-treatment resection specimens of the 20 patients with non-small-cell lung carcinoma who underwent definitive surgery. Pretreatment tumor biopsies and preresection radiographic 'tumor' measurements were also assessed. Results We found that the regression bed (the area of immune-mediated tumor clearance) accounts for the previously noted discrepancy between CT imaging and pathologic assessment of residual tumor. The regression bed is characterized by (i) immune activation-dense tumor infiltrating lymphocytes with macrophages and tertiary lymphoid structures; (ii) massive tumor cell death-cholesterol clefts; and (iii) tissue repair-neovascularization and proliferative fibrosis (each feature enriched in major pathologic responders versus nonresponders, P < 0.05). This distinct constellation of histologic findings was not identified in any pretreatment specimens. Histopathologic features of the regression bed were used to develop 'Immune-Related Pathologic Response Criteria' (irPRC), and these criteria were shown to be reproducible amongst pathologists. Specifically, %irRVT had improved interobserver consistency compared with %cRVT [median per-case %RVT variability 5% (0%-29%) versus 10% (0%-58%), P = 0.007] and a twofold decrease in median standard deviation across pathologists within a sample (4.6 versus 2.2, P = 0.002). Conclusions irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.
Collapse
Affiliation(s)
- T R Cottrell
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA
| | - E D Thompson
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - P M Forde
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - J E Stein
- Department of Dermatology, Johns Hopkins University SOM, Baltimore, USA
| | - A S Duffield
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA
| | - V Anagnostou
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - N Rekhtman
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R A Anders
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - J D Cuda
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Dermatology, Johns Hopkins University SOM, Baltimore, USA
| | - P B Illei
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - E Gabrielson
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - F B Askin
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA
| | - N Niknafs
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - K N Smith
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - M J Velez
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J L Sauter
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J M Isbell
- Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
| | - D R Jones
- Thoracic Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
| | - R J Battafarano
- Department of Surgery, Johns Hopkins University SOM, Baltimore, USA
| | - S C Yang
- Department of Surgery, Johns Hopkins University SOM, Baltimore, USA
| | - L Danilova
- The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA; Division of Biostatistics and Bioinformatics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - J D Wolchok
- Melanoma and Immunotherapeutics Service, Division of Solid Tumor Oncology, Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA; Weill Cornell Medical College, New York, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA
| | - S L Topalian
- The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA; Department of Surgery, Johns Hopkins University SOM, Baltimore, USA
| | - V E Velculescu
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - D M Pardoll
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - J R Brahmer
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA
| | - M D Hellmann
- Weill Cornell Medical College, New York, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J E Chaft
- Weill Cornell Medical College, New York, USA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - A Cimino-Mathews
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA
| | - J M Taube
- Department of Pathology, Johns Hopkins University SOM, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA; The Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, USA; Department of Dermatology, Johns Hopkins University SOM, Baltimore, USA.
| |
Collapse
|
11
|
Zhang J, Ji Z, Caushi J, El Asmar M, Anagnostou V, Cottrell T, Chan H, Guo H, Merghoub T, Chaft J, Wolchok J, Reuss J, Marrone K, Naidoo J, Gabrielson E, Taube J, Brahmer J, Velculescu V, Zhao N, Hellmann M, Forde P, Pardoll D, Yegnasubramanian S, Ji H, Smith K. MA11.10 Peripheral T Cell Repertoire Evolution in Resectable NSCLC Treated with Neoadjuvant PD-1 Blockade. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
El Asmar M, Zhang J, Caushi J, Ji Z, Anagnostou V, Cottrell T, Chan H, Suri P, Guo H, Marrone K, Naidoo J, Merghoub T, Chaft J, Hellmann M, Taube J, Brahmer J, Forde P, Velculescu V, Pardoll D, Ji H, Smith K. MA04.11 Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD-1 Blockade. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Forde P, Smith K, Chaft J, Hellmann M, Merghoub T, Wolchok J, Yang S, Battafarano R, Gabrielson E, Georgiades C, Verde F, Rosner G, Naidoo J, Cottrell T, Taube J, Anagnostou V, Velculescu V, Topalian S, Pardoll D, Brahmer J. NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.38] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Anagnostou V, Papa A. Prevalence of antibodies to phleboviruses within the sand fly fever Naples virus species in humans, northern Greece. Clin Microbiol Infect 2013; 19:566-70. [DOI: 10.1111/j.1469-0691.2012.03957.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
15
|
Neumeister VM, Lostritto K, Siddiqui S, Anagnostou V, Vassilakopoulou M, Zarrella EA, Molinaro AM, Hicks DG, Rimm DL. P1-07-03: Preanalytical Variables Affect Protein Expression in Formalin Fixed Paraffin Embedded Tissue – Assessment of Intrinsic Controls To Define Tissue Quality for Immunohistochemical Analysis. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recently it has been shown that biospecimen handling and pre-analytical variables can dramatically affect biomarker assays of protein expression in tumor tissue. Phospho-proteins and even labile unmodified proteins have been suggested to show significant loss of expression due to prolonged time to formalin fixation. Here we assess 4 clinically relevant proteins (ER, PR, HER2 and Ki67) and 20 other proteins for changes as a function to the key preanalytic variables of ischemic time. The ultimate goal of our effort is to find a method to monitor the degradative effect of these variables by construction of a Tissue Quality Index (TQI).
Materials and Methods: Two different breast cancer cohorts were used in order to analyze the biomarkers and their change according to time to formalin fixation. The first cohort consists of 93 breast cancer specimens in 2 fold redundancy on a TMA with cell lines and controls. The time to formalin fixation for each breast cancer specimen was recorded and ranges from 25 to 415 minutes. The second cohort consists of 25 matched pairs of breast cancer biopsies and resections. The time to formalin fixation for the biopsies is minimal while the time to fixation for the resections, though not recorded, averages between 1 and 3 hours. Protein expression was measured using the AQUA method of quantitative immunofluorescence.
Results: ER alpha, PR, HER2 and Ki67 were each analyzed on the time to fixation array with 2 different antibodies commonly used in the clinical setting. Correlation of AQUA scores of these markers with time to formalin fixation revealed a trend towards loss of protein expression as a linear function of time to fixation without reaching statistical significance. Analysis of these 4 proteins on the matched pairs of biopsies and resections showed that tumor heterogeneity predominated over the effects of ischemic time. Toward identification of markers for a TQI, 20 biomarkers were analyzed on the time to fixation array. Both HIF1alpha and AKAP13 show a significant increase as a function of time to fixation, whereas pMAPK, histone 4 and pTyrosine 4G10 revealed a significant loss of expression. These trends were confirmed in the matched pair validation set with the execption of histone 4. A TQI is being built from these variables.
Conclusions: Ischemic time is a critical pre-analytical variable that impacts measurement of protein expression in tumor tissue. The 4 standard markers used clinically in breast cancer appear to show only moderate effects that appear less critical to measurement accuracy than the issue of tumor heterogeneity. We identified 4 proteins which show a significant change with increasing time to formalin fixation and should allow construction of a TQI for assessment of pre-analytic antigenic degradation.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-07-03.
Collapse
Affiliation(s)
- VM Neumeister
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - K Lostritto
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - S Siddiqui
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - V Anagnostou
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - M Vassilakopoulou
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - EA Zarrella
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - AM Molinaro
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - DG Hicks
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| | - DL Rimm
- 1Yale University School of Medicine, New Haven, CT; Rochester University, School of Medicine, Rochester, NY
| |
Collapse
|
16
|
Abrahim A, Sergelidis D, Kirkoudis I, Anagnostou V, Kaitsa-Tsiopoulou E, Kazila P, Papa A. Isolation and Antimicrobial Resistance ofStaphylococcusspp. in Freshwater Fish and Greek Marketplaces. Journal of Aquatic Food Product Technology 2010. [DOI: 10.1080/10498850.2010.491597] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Anagnostou V, Lowery F, Syrigos K, Frangia K, Zolota V, Panagopoulos N, Dougenis D, Tanoue L, Detterbeck F, Homer R, Rimm D. Association of expression of bcl-2 with outcome in non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22039 Background: BCL-2 promotes cell survival by inhibiting adapters needed for the activation and cleavage of caspases thus blocking the proteolytic cascade that ultimately dismantles the cell. It is preferentially expressed in squamous cell carcinomas of the lung and has been investigated as a potential prognostic parameter in lung cancer patients with conflicting results. Here, we quantitatively assessed BCL-2 protein expression in two large and independent data sets to investigate the impact of BCL-2 on patient survival. Methods: AQUA, a fluorescent-based method for analysis of in situ protein expression, was used to measure BCL-2 protein levels and classify tumor by BCL-2 expression in a cohort of 180 lung cancer patients from Yale New Haven Hospital (training set). An independent cohort of 360 lung cancer patients from Sotiria General Hospital and Patras University Hospital in Greece was used to validate BCL-2 classification and evaluate outcome (validation set). Results: Tumors expressed BCL-2 in 57% and 53% of the cases in training and validation cohorts respectively and squamous cell carcinomas expressed higher levels of BCL-2 expression compared to adenocarcinomas (mean AQUA score 42 and 26 respectively, p=0.007); BCL-2 was not associated with other standard clinical or pathological characteristics. Survival analysis showed that patients with high BCL-2 expression had a longer median overall survival compared to the low expressers (20 vs 15 months, log rank p=0.016). Multivariate analysis revealed an independent lower risk of death for lung cancer patients with BCL-2 expressing tumors (HR=0.58, 95% CI 0.39–0.86, p=0.006). Conclusions: BCL-2 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of lung cancer patients as well as incorporation of BCL-2 into clinical decisions. [Table: see text]
Collapse
Affiliation(s)
- V. Anagnostou
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - F. Lowery
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - K. Syrigos
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - K. Frangia
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - V. Zolota
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - N. Panagopoulos
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - D. Dougenis
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - L. Tanoue
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - F. Detterbeck
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - R. Homer
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| | - D. Rimm
- Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, New Haven, CT; Yale Cancer Center, Yale University School of Medicine, New Haven, CT; Sotiria General Hospital, Athens, Greece; University of Patras, Patras, Greece
| |
Collapse
|
18
|
Floros G, Anagnostou V, Tsiga E, Ferenidou F, Papadimitriou D. Using statins to reduce cardiovascular risk after carotid endarterectomy. Evid Based Cardiovasc Med 2006; 10:1-4. [PMID: 16530653 DOI: 10.1016/j.ebcm.2006.01.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Affiliation(s)
- G Floros
- Aristotle University of Thessaloniki Medical School, Greece
| | | | | | | | | |
Collapse
|